连续性静脉-静脉血液滤过联合血液灌流治疗急性百草枯中毒的疗效:一项前瞻性对照试验
这项单中心、前瞻性对照干预研究纳入上海第十人民医院48小时内百草枯中毒患者110例,连续性静脉-静脉血液滤过组59例接受连续性静脉-静脉血液滤过联合血液灌流,常规组51例接受常规治疗。90天随访,连续性静脉-静脉血液滤过组死亡19/59(32.2%),常规组死亡29/51(56.9%),HR 0.43(95%CI 0.24-0.76,p=0.004);多因素Cox模型校正基线特征后,联合治疗与死亡风险降低独立相关(校正HR 0.35,95%CI 0.19-0.64,p=0.001)。连续性静脉-静脉血液滤过组缺氧发生率40.7% vs 常规组72.5%(p=0.001),急性肾损伤发生率59.3% vs 78.4%(p=0.03),低磷血症和血小板减少更常见(p<0.05)。
要点
- 百草枯中毒48小时内入院的患者,连续性静脉-静脉血液滤过联合血液灌流组90天死亡率32.2%(19/59)vs 常规治疗组56.9%(29/51),HR 0.43(95%CI 0.24-0.76,p=0.004)。
- 多因素Cox模型校正基线特征后,联合治疗与死亡风险降低独立相关,校正HR 0.35(95%CI 0.19-0.64,p=0.001)。
- 联合治疗组缺氧发生率40.7% vs 常规组72.5%(p=0.001),急性肾损伤发生率59.3% vs 78.4%(p=0.03)。
- 联合治疗组低磷血症和血小板减少更常见(p<0.05)。
- 研究排除<14岁、混合中毒、妊娠、慢性肺病、精神病、甲亢或糖尿病伴肝肾功能损害者。
适用人群与场景
- 上海第十人民医院收治的百草枯摄入后48小时内入院患者。
- 排除:年龄<14岁、百草枯与其他毒物混合摄入、妊娠、慢性肺病病史、精神病、甲亢或糖尿病伴肝肾功能损害。
处置流程与药物剂量
- 连续性静脉-静脉血液滤过组:接受连续性静脉-静脉血液滤过联合血液灌流治疗。
- 常规组:接受常规治疗。
研究设计与关键结果
- 研究类型:前瞻性、对照干预研究,历时4年,单中心、三级学术医疗中心,纳入110例百草枯中毒患者,连续性静脉-静脉血液滤过组59例,常规组51例,两组基线人口学和临床特征相似。
- 主要终点:90天全因死亡,连续性静脉-静脉血液滤过组19/59(32.2%)vs 常规组29/51(56.9%),HR 0.43(95%CI 0.24-0.76,p=0.004)。
- 多因素Cox比例风险模型校正基线特征后,联合连续性静脉-静脉血液滤过和血液灌流与常规治疗相比,死亡风险独立降低,校正HR 0.35(95%CI 0.19-0.64,p=0.001)。
- 次要终点:缺氧发生率连续性静脉-静脉血液滤过组40.7% vs 常规组72.5%(p=0.001);急性肾损伤发生率59.3% vs 78.4%(p=0.03)。
- 不良事件:低磷血症和血小板减少在连续性静脉-静脉血液滤过组更常见(p<0.05)。
证据类型、等级与局限
- 证据类型:前瞻性、对照干预研究,单中心。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,百草枯中毒患者接受连续性静脉-静脉血液滤过联合血液灌流治疗显著改善了90天生存率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate whether combined continuous venovenous hemofiltration and hemoperfusion among paraquat-poisoned patients would improve survival.
DESIGN: Prospective, controlled interventional study over 4 years.
SETTING: Single, tertiary, academic medical center.
PATIENTS: We recruited patients admitted to Shanghai Tenth People's Hospital within 48 hours after paraquat ingestion. Exclusions were under 14 years old, ingestion of paraquat with other toxicants, pregnant, a history of chronic pulmonary disease, psychosis, hyperthyroidism, or diabetes with impaired liver or renal function.
INTERVENTIONS: All patients were assigned to receive continuous venovenous hemofiltration with hemoperfusion therapy (continuous venovenous hemofiltration group) and to receive conventional therapy (conventional group). The study outcomes were death from any cause within 90 days after paraquat ingestion and the frequencies of hypoxia, acute kidney injury, or adverse events.
MEASUREMENTS AND MAIN RESULTS: Of the 110 enrolled patients, 59 were assigned to continuous venovenous hemofiltration group and 51 to conventional group. The two groups had similar baseline demographics and clinical features. At 90 days after paraquat ingestion, 19 of 59 patients (32.2%) in the continuous venovenous hemofiltration group and 29 of 51 patients (56.9%) in the conventional group had died (hazard ratio, 0.43; 95% CI, 0.24-0.76; p = 0.004). In multivariable Cox proportional hazard models controlling for baseline characteristics, combined continuous venovenous hemofiltration and hemoperfusion was independently associated with reduced risk of death compared with conventional therapy (adjusted hazard ratio, 0.35; 95% CI, 0.19-0.64; p = 0.001). Patients in the continuous venovenous hemofiltration group, as compared to the conventional group, had a reduced occurrence rate of hypoxia (40.7% vs 72.5%; p = 0.001) and of acute kidney injury (59.3% vs 78.4%; p = 0.03). Hypophosphatemia and thrombocytopenia were more common in the continuous venovenous hemofiltration group (p < 0.05).
CONCLUSIONS: In patients with paraquat poisoning, treatment with combined continuous venovenous hemofiltration and hemoperfusion significantly improved 90-day survival rates.
参考来源
- Li C, Hu D, Xue W, et al. Treatment Outcome of Combined Continuous Venovenous Hemofiltration and Hemoperfusion in Acute Paraquat Poisoning: A Prospective Controlled Trial. Crit Care Med. 2018. PMID: 29116999. doi:10.1097/CCM.0000000000002826
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。